Splenic switch-off in regadenoson 82Rb-PET myocardial perfusion imaging: assessment of clinical utility

J Nucl Cardiol. 2023 Aug;30(4):1484-1496. doi: 10.1007/s12350-022-03158-3. Epub 2023 Jan 6.

Abstract

Background: Splenic switch-off (SSO) is a phenomenon describing a decrease in splenic radiotracer uptake after vasodilatory stress. We aimed to assess the diagnostic utility of regadenoson-induced SSO.

Methods: We included consecutive patients who had clinically indicated Regadenoson Rb-82 PET-MPI for suspected CAD. This derivation cohort (no perfusion defects and myocardial flow reserves (MFR) ≥ 2) was used to calculate the splenic response ratio (SRR). The validation cohort was defined as patients who underwent both PET-MPI studies and invasive coronary angiography (ICA).

Results: The derivation cohort (n = 100, 57.4 ± 11.6 years, 77% female) showed a decrease in splenic uptake from rest to stress (79.9 ± 16.8 kBq⋅mL vs 69.1 ± 16.2 kBq⋅mL, P < .001). From the validation cohort (n = 315, 66.3 ± 10.4 years, 67% male), 28% (via SRR = 0.88) and 15% (visually) were classified as splenic non-responders. MFR was lower in non-responders (SRR; 1.55 ± 0.65 vs 1.76 ± 0.78, P = .02 and visually; 1.18 ± 0.33 vs 1.79 ± 0.77, P < .001). Based on ICA, non-responders were more likely to note obstructive epicardial disease with normal PET scans especially in patients with MFR < 1.5 (SRR; 61% vs 34% P = .05 and visually; 68% vs 33%, P = .01).

Conclusion: Lack of splenic response based on visual or quantitative assessment of SSO may be used to identify an inadequate vasodilatory response.

Keywords: Myocardial perfusion imaging; positron emission tomography; regadenoson; spleen; splenic switch-off; vasodilatory agent.

MeSH terms

  • Coronary Artery Disease* / diagnostic imaging
  • Female
  • Humans
  • Male
  • Myocardial Perfusion Imaging*
  • Positron-Emission Tomography
  • Purines / pharmacology
  • Rubidium Radioisotopes

Substances

  • regadenoson
  • Rubidium-82
  • Rubidium Radioisotopes
  • Purines